<DOC>
	<DOCNO>NCT02218619</DOCNO>
	<brief_summary>Clinically , ability slow prevent beta cell demise prevent improve course type 1 diabetes . The immune-mediated destruction beta cell apparent major pathological basis disease , lead effort prevent suppress immune assault . Here propose buttress beta cell 's capacity withstand assault improve function endoplasmic reticulum stress resolve mechanism within cell . The ability could major impact preventive therapeutic strategy type 1 diabetes ( possibly type diabetes ) . The type endoplasmic reticulum stress relieve agent ( TUDCA ) propose could ultimately applied anticipatory basis individual high risk type 1 diabetes .</brief_summary>
	<brief_title>Tauroursodeoxycholic Acid ( TUDCA ) New-Onset Type 1 Diabetes</brief_title>
	<detailed_description>Reducing endoplasmic reticulum stress promote beta cell survival new-onset type 1 diabetes . The primary aim test clinical efficacy already approve agent , TUDCA , re-purposed reduce endoplasmic reticulum stress improve beta cell survival patient new onset type 1 diabetes . The primary endpoint propose double-blinded randomized placebo-controlled pilot study c-peptide measure mixed meal stimulation test randomization 6 12 month treatment TUDCA compare treatment placebo 6 month follow treatment . TUDCA oral medication excellent safety profile approve use Europe gall stone liver disease . The drug similar compound used child , young newborn , adult . TUDCA 's ability lower endoplasmic reticulum stress recently recognize applied new-onset type 1 diabetes proposal . If pilot trial successful , future study could include broaden recipient antibody-positive pre-type 1 diabetes patient and/or combine TUDCA agent show beneficial effect insulin secretion new-onset type 1 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<criteria>Type 1 diabetes accord American Diabetes Association criterion Diagnosis type 1 diabetes within 100 day randomization One positive diabetesrelated autoantibody Ages 1845 year Drugs know affect glucose insulin Stimulated Cpeptide level &lt; 0.2 pmol/ml measure mixed meal tolerance test conduct least 21 day diagnosis diabetes within one month ( 37 day ) randomization either TUDCA placebo . Women pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>type 1 diabetes ( T1D )</keyword>
	<keyword>endoplasmic reticulum ( ER ) stress</keyword>
	<keyword>induce pluripotential stem ( iPS ) cell</keyword>
	<keyword>Tauroursodeoxycholic Acid ( TUDCA )</keyword>
</DOC>